AZD4625 chemical structure, oral KRAS(G12C) inhibitor - AstraZeneca, Cambridge, UK

oral KRAS(G12C) inhibitor

oral efficacy in xenograft model

from literature starting point and SBDD

J. Med. Chem.

AstraZeneca, Cambridge, UK

Context. AZD4625 (AstraZeneca) is an oral inhibitor of KRASG12C being developed for the treatment of advanced solid malignancies. As indicated for JDQ443, the KRASG12C mutation presents the perfect “Achilles…

 this content is exclusive to
Premium members

Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.